THANK YOU FOR SUBSCRIBING
The changes in the conventional business processes of a pharmaceutical company are enabling the removal of substantial expenses from the supply chain.
FREMONT, CA: Manufacturing and supply chain processes create a wealth of data. The data created by traditional ways have always remained in the place where it has been generated, limiting its ability to deliver value. The disruption in the traditional business processes of a pharmaceutical company, particularly the shift to value-based pricing for pharmaceutical products, is causing managers to remove substantial expenses from the supply chain.
In a study conducted by Accenture Research, it shows that a partial digitization approach for a $10 billion pharmaceutical company allows upwards of $387 million in manufacturing and production process costs to be taken out. To recognize the critical savings information from digital conversion, sound information management procedures are needed.
Increased collaboration with supply chain partners, changes in international regulations, and supervision to safeguard the pharmaceutical supply chain also require trusted information accessibility. It is now commonly acknowledged that achievement in the pharmaceutical industry is becoming increasingly dependent on the ability to turn data into useful information.
The pharmaceutical industry is caught up in the digital disruption. Those companies will become successful, which can manage, use, and share data in this new data-fuelled transformation system. Pharmaceutical organizations that enable their supply chain staff and business processes through trusted data can realize tremendous cost savings through:
• Improved supplier procurement contracts
• Increased efficiency in manufacturing
• Collaboration with supply chain patterns is more effective
• Manage performance in real time
• Fulfill orders reliably with fewer touches
• Leverage new technologies to further improve processes.
As the pharmaceutical industry continues to evolve day by day, businesses can no longer afford to withstand the use of digital techniques and instruments. In this constantly changing landscape, pharmaceutical companies seeking strategic benefit are finding many fresh methods to leverage digital alternatives and will have a better opportunity of remaining competitive and flexible.